M.J. v. Frank Bisignano, Commissioner of Social Security

CourtDistrict Court, D. South Dakota
DecidedFebruary 11, 2026
Docket4:25-cv-04080
StatusUnknown

This text of M.J. v. Frank Bisignano, Commissioner of Social Security (M.J. v. Frank Bisignano, Commissioner of Social Security) is published on Counsel Stack Legal Research, covering District Court, D. South Dakota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
M.J. v. Frank Bisignano, Commissioner of Social Security, (D.S.D. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF SOUTH DAKOTA SOUTHERN DIVISION

M.J., 4:25-CV-04080-VLD

Plaintiff, MEMORANDUM OPINION AND ORDER vs.

FRANK BISIGNANO, COMMISSIONER OF SOCIAL SECURITY;

Defendant.

INTRODUCTION Plaintiff M.J. seeks judicial review of the Commissioner’s final decision denying her application for Social Security disability benefits under Title II and Title XVI of the Social Security Act.1 Ms. J requests reversal of the

1SSI benefits are called “Title XVI” benefits, and SSD/DIB benefits are called “Title II” benefits. Receipt of both forms of benefits is dependent upon whether the claimant is disabled. The definition of disability is the same under both Titles. The difference—greatly simplified—is that a claimant’s entitlement to SSD/DIB benefits is dependent upon one’s “coverage” status (calculated according to one’s earning history), and the amount of benefits are likewise calculated according to a formula using the claimant’s earning history. There are no such “coverage” requirements for SSI benefits, but the potential amount of SSI benefits is uniform and set by statute, dependent upon the claimant’s financial situation, and reduced by the claimant’s earnings, if any. There are corresponding and usually identical regulations for each type of benefit. See, e.g., 20 C.F.R. §§ 404.1520 & 416.920 (evaluation of disability using the five- step procedure under Title II and Title XVI). Ms. J. filed her application for both types of benefits. AR17. Commissioner’s final decision denying her disability benefits, and remand of the matter to the Social Security Administration for further proceedings. See Docket No. 11. The Commissioner seeks affirmance of the agency’s decision

below. See Docket No. 12. This appeal of the Commissioner’s final decision denying benefits is properly before the court pursuant to 42 U.S.C. § 405(g). The parties have consented to this magistrate judge handling this matter pursuant to 28 U.S.C. § 636(c). FACTS A. Procedural History Ms. J. applied for disability benefits under Title II and Title XVI of the

Social Security Act, alleging a date of disability of April 27, 2022. AR17. Ms. J.’s application was denied initially and again upon reconsideration. Id. A telephonic hearing was held before an ALJ, who found Ms. J. not disabled. AR 27, 34. Ms. J.’s request for review of the Appeals Council was denied. AR 1-3. The issue before the Court is whether the ALJ’s residual functional capacity (“RFC”) finding is deficient because it does not account for the total limiting effects of Plaintiff’s migraine impairments. Docket No. 11 at 1. Accordingly, the court discusses below only the medical records relevant to

Ms. J’s migraines. B. Medical Evidence 1. Records Predating Alleged Onset of Disability a. Colorado Records

In a December 11, 2015, visit to the emergency room for right ankle pain, it was noted that Ms. J. was prescribed Topamax and acyclovir for migraines, but that she was not taking them. AR 846. On December 13, 2018, Ms. J attended an appointment at the University of Colorado Health Neurology Clinic (UCHealth). AR 766. Ms. J.’s provider diagnosed Ms. J. with migraines that were “not intractable” and “with aura and without status migrainosus.”2 Id. At this appointment Ms. J. told her provider that she has a history of complex migraines dating back to when she was 17

years old, primarily in the bilateral frontal region. AR 767. She reported that she was having headaches daily, and that before her migraines, she sees spots in her vision. Id. Ms. J. also experienced photophobia,3 phonophobia,4 nausea, and vomiting during the migraines. Id.

2 Status Migrainosus is defined as “a migraine attack that lasts longer than 72 hours.” Status Migrainosus, https://my.clevelandclinic.org/health/diseases/status-migrainosus (last visited February 2, 2026).

3 Photophobia is defined as “[e]xcessive sensitivity to, or intolerance of, light.” Photophobia, ATTORNEYS' DICTIONARY OF MEDICINE (No. 59, 2025).

4 Phonophobia is defined as “[a] condition of extreme intolerance or fear of sounds and noises.” Phonophobia, ATTORNEYS' DICTIONARY OF MEDICINE (No. 59, 2025). Ms. J’s primary care physician prescribed rizatriptan and Topamax to treat her migraines. Id. Ms. J. told the provider that she had not yet started Topamax because she did not know how to use it. Id. The provider advised

Ms. J. to discontinue rizatriptan because Ms. J.’s stroke contraindicated the use of triptans. AR 767-768. Ms. J was also prescribed Flexeril.5 AR 768. On June 6, 2019, Ms. J. reported having over 15 headaches a month, and at least eight of those were migraine days. AR 761. The migraines lasted over four hours. Id. Ms. J had began using her Topamax following her appointment in December of 2018. Id. At this appointment, her provider noted that Ms. J. “has trialed and failed to oral preventative pharmacological agents listed as level a per American headache Society/American Academy of

neurology (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction).” Id. Ms. J. found Topamax mildly effective but suffered from side effects. Id. In its place, a trial run of Emgality6 was prescribed. AR 761-762. It appears Flexiril was discontinued. AR 762. At a June 26, 2019, doctor visit, Ms. J. reported worsening headaches. AR 756. On January 9, 2020, Ms. J. had been using Emgality for six months, and it had been working quite well for Ms. J. until 3 weeks prior to the visit. AR

5 Flexeril is “[t]he trademark name of medicinal tablets used for muscle spasm.” Flexeril, ATTORNEYS' DICTIONARY OF MEDICINE (No. 59, 2025).

6 Emgality is “[t]he trademark name of a drug intended for use in prevention of migraine and in treatment of episodic cluster headache.” Emgality, ATTORNEYS' DICTIONARY OF MEDICINE (No. 59, 2025). 751. Ms. J. described having a significant rise in the number of migraines she experienced in the last three weeks. Id. Her provider discussed Botox injections and Aimovig7 as possible substitute medications. Id. Ms. J. chose to

try Botox. Id. On February 6, 2020, Ms. J. had her first Botox injection to treat her migraines. AR 749. In an April 30, 2020, appointment, Ms. J. informed her provider that she had previously experienced migraines 30 times a month, but with Botox she had no migraines. AR 747. Ms. J. reported that the Botox had worn off some in the last two weeks before her next injection. Id. She had a second Botox shot. AR 748. Ms. J had her third Botox shot on September 3, 2020. AR 743- 44. The provider noted Ms. J should repeat the injection in 3 months. AR 744.

On September 4, 2020, Ms. J. attended an appointment regarding her migraines. AR 739. The medical plan was to continue Botox which her provider noted caused “a greater than 75% reduction in intensity, frequency and duration of migraines.” Id. Ms. J. reported the Botox worked “extremely well” and reduced her migraines to only three in three months. Id. Ms. J. reported that when she did have migraines, they occurred one to three weeks prior to her next injection. Id. On February 11, 2021, Ms. J. received a Botox injection. AR 731-32.

b. South Dakota Records

7 Aimovig is “[t]he trademark name of a drug intended for use in prevention of migraine.” Aimovig, ATTORNEYS' DICTIONARY OF MEDICINE (No. 59, 2025). On September 8, 2021, Ms. J.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brown v. Apfel
192 F.3d 492 (Fifth Circuit, 1999)
Richardson v. Perales
402 U.S. 389 (Supreme Court, 1971)
Heckler v. Campbell
461 U.S. 458 (Supreme Court, 1983)
Walker v. Bowen
834 F.2d 635 (Seventh Circuit, 1987)
Smith v. Shalala
987 F.2d 1371 (Eighth Circuit, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
M.J. v. Frank Bisignano, Commissioner of Social Security, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mj-v-frank-bisignano-commissioner-of-social-security-sdd-2026.